Erythromycin

Introduction Overview

Generic Name

erythromycin

Brand Name

E.E.S. Granules
E.E.S.-200
E.E.S.-400 Filmtab
EryPed 200
EryPed 400
Ery-Tab
Erythrocin Lactobionate
Erythrocin Stearate Filmtab

Dosage Form

oral (tablet, chewable tablet, delayed-release capsule, suspension), injection (intravenous infusion)

Drug Class

Macrolides

Pharmacokinetics

Absorption:
Erythromycin is variably absorbed in the gastrointestinal tract. The absorption primarily occurs in the small intestine rather than the stomach, leading to the development of enteric-coated and delayed-release formulations to protect it from acidic gastric pH. Oral bioavailability ranges approximately 30–65%, with substantial variability among individuals. Food intake can reduce erythromycin absorption, and as such, the drug is often recommended to be taken on an empty stomach to maximize plasma concentrations. Several formulations like erythromycin estolate and ethylsuccinate have unique absorption characteristics; for example, erythromycin ethylsuccinate exhibits improved oral bioavailability.

Distribution:
Following absorption, erythromycin exhibits extensive tissue distribution with higher concentrations found in the liver, lungs, skin, and other soft tissues relative to plasma levels. It crosses the placenta but does not readily cross the blood-brain barrier, limiting central nervous system penetration. Erythromycin is approximately 70-90% bound to plasma proteins, primarily albumin. Its large volume of distribution (estimated between 1 and 1.5 L/kg) reflects extensive tissue uptake. The drug accumulates in phagocytic cells, which contributes to its efficacy in intracellular bacterial infections.

Metabolism:
Erythromycin undergoes hepatic metabolism predominantly via cytochrome P450 enzymes, especially CYP3A4. It is extensively metabolized to inactive metabolites, with a significant portion subject to first-pass hepatic metabolism which influences its bioavailability. The drug can cause CYP3A4 inhibition, leading to clinically significant drug interactions. The metabolism rate may be affected by liver disease or concomitant medications that induce or inhibit hepatic enzymes.

Elimination:
Erythromycin is primarily eliminated via hepatic excretion into the bile, with only a small percentage (approximately 5-15%) excreted unchanged in the urine. The enterohepatic circulation plays a role in prolonging its half-life. The plasma elimination half-life ranges from 1.5 to 2 hours in individuals with normal hepatic function. In patients with hepatic impairment, clearance is reduced, necessitating careful dose adjustment. Erythromycin’s renal clearance is minimal, and it is not reliably removed by hemodialysis. The pharmacokinetics thus require consideration of liver function during therapy.

Dosage Forms

Available Dosage Forms:
Erythromycin is available in multiple oral and parenteral dosage forms designed to optimize bioavailability and patient compliance. Oral dosage forms include:
- Oral capsules (delayed-release/enteric-coated): typically 250 mg, 333 mg, and 500 mg strengths
- Tablets: film-coated tablets available in 200 mg and 400 mg doses
- Chewable tablets: e.g., 200 mg, 400 mg strengths, requiring chewing prior to swallowing
- Oral suspension/liquid preparations: available in varying concentrations such as 125 mg/5 mL, 200 mg/5 mL, and 400 mg/5 mL for pediatric and adult use
- Granules for oral suspension (e.g., E.E.S. granules)
Intravenous formulations include:
- Erythromycin lactobionate injection available as sterile powder for reconstitution administered via intravenous infusion

Dosages for Adults and Adolescents:
Dosing regimens vary according to the severity and type of infection. Commonly, oral erythromycin dosing ranges from 250 mg to 500 mg every 6 to 12 hours. For serious infections requiring intravenous therapy, doses typically range from 250 mg to 500 mg every 6 hours, adjusted based on clinical response and patient factors. Duration of therapy typically ranges from 7 to 14 days or more, depending on infection severity and site.

Specific Patient Populations:
Pediatric dosing is weight-based, typically 30-50 mg/kg/day divided every 6 to 12 hours. Specialized formulations such as suspensions and granules facilitate administration in infants and children. In patients with hepatic impairment, dosage adjustments and monitoring are necessary due to decreased metabolism and clearance. In renal impairment, no significant dose adjustment is required as the drug is predominantly eliminated hepatically. Geriatric dosing generally follows standard adult regimens but with caution due to potential increased incidence of side effects such as hearing loss. Pregnant and breastfeeding women require careful risk-benefit consideration; erythromycin is classified as relatively safe but should be used under medical supervision.

Mechanism Of Action

Erythromycin is a macrolide antibiotic that exerts its bacteriostatic action by binding to the 50S subunit of bacterial ribosomes. This binding inhibits the translocation steps in protein synthesis, effectively blocking the elongation of the nascent protein chain. By interfering with the peptidyl transferase activity, erythromycin prevents the formation of peptide bonds, crucial for bacterial growth and replication.

At the molecular level, erythromycin’s affinity for the 50S ribosomal subunit prevents the movement of tRNA and mRNA through the ribosome, thus halting bacterial protein synthesis. This inhibition disrupts the production of essential proteins required for bacterial cell maintenance and replication, leading to bacteriostatic effects. In some bacterial species and at higher drug concentrations, erythromycin can exert bactericidal effects.

Clinically, erythromycin’s mechanism allows it to be effective against a broad spectrum of Gram-positive bacteria and some Gram-negative organisms, especially intracellular pathogens such as Legionella pneumophila and Mycoplasma pneumoniae. Compared to other macrolides such as azithromycin and clarithromycin, erythromycin has similar binding targets but differs in pharmacokinetics and resistance profiles.

Extensive research supports erythromycin’s protein synthesis inhibition as the primary mechanism, with resistance emerging predominantly through methylation of 23S rRNA, mutation of ribosomal binding sites, and efflux pumps. Understanding erythromycin’s mode of action has guided the development of newer macrolides with improved pharmacologic properties and resistance profiles.

Pharmacological Actions

Bacteriostatic inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit
Broad-spectrum activity against Gram-positive cocci, some Gram-negative bacilli, and atypical pathogens
Effectiveness against intracellular bacteria such as Legionella, Mycoplasma, and Chlamydia species
Interference with bacterial ribosomal translocation processes, halting peptide chain elongation
Inhibition of bacterial growth with bactericidal effects at high concentrations or against highly susceptible organisms
Enhanced accumulation within phagocytic cells, aiding eradication of intracellular pathogens
Moderate anti-inflammatory properties due to inhibition of neutrophil chemotaxis and cytokine production
Potential prokinetic effect on gastrointestinal motility via motilin receptor agonism (clinically limited)
Inhibition of cytochrome P450 3A4 enzymes affecting metabolism of concurrent medications
Minimal activity against beta-lactamase producing organisms without combination therapy
Participation in enterohepatic recycling, prolonging plasma half-life and tissue exposure
Resistance mechanisms include target site modification and efflux pumps, impacting clinical efficacy
Used as an alternative antibiotic in patients with penicillin allergies
Exhibits post-antibiotic effect contributing to prolonged bacterial suppression after dosing
Synergistic effects in combination with other antimicrobials against certain pathogens

Therapeutic Or Clinical Uses

Treatment of respiratory tract infections including bronchitis, pneumonia, and pertussis
Management of skin and soft tissue infections caused by susceptible strains
Therapy of sexually transmitted infections like chlamydia and syphilis
Prevention and treatment of bacterial endocarditis in at-risk patients undergoing dental or surgical procedures
Treatment of gastrointestinal infections such as campylobacteriosis and diphtheria
Management of atypical mycobacterial infections in immunocompromised patients
Topical and systemic treatment of acne vulgaris
Use in pediatric infections where penicillin is contraindicated
Prophylaxis of disseminated Mycobacterium avium complex (MAC) infection in HIV/AIDS
Treatment of pelvic inflammatory disease caused by susceptible organisms
Management of Legionnaires’ disease
Alternative therapy in Helicobacter pylori eradication regimens
Treatment of pertussis (whooping cough) to reduce transmission
Eradication of nasopharyngeal carriage of group A Streptococcus
Use in otitis media and sinusitis when caused by susceptible bacteria

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, abdominal pain, and diarrhea
Risk of antibiotic-associated diarrhea and pseudomembranous colitis caused by Clostridioides difficile
Transient hearing loss or ototoxicity, more commonly in elderly patients or high doses
Allergic reactions such as rash, urticaria, and rare anaphylaxis
Hepatotoxicity including cholestatic hepatitis, elevated liver enzymes, and rare liver failure
QT interval prolongation leading to arrhythmias such as torsades de pointes and sudden cardiac death
Headache, dizziness, and nervous system effects including seizures rarely reported
Pancreatitis characterized by severe upper abdominal pain, nausea, and vomiting
Superinfection with resistant organisms or fungi during prolonged therapy
Injection site reactions including pain, phlebitis, or inflammation with intravenous formulations
Exacerbation of myasthenia gravis symptoms
Rare occurrence of blood dyscrasias such as thrombocytopenia or neutropenia
Development of erythema multiforme and other severe skin reactions rarely reported
Interactions leading to increased serum concentrations of concomitant drugs causing toxicity
Hypersensitivity pneumonitis and pulmonary eosinophilia as rare idiosyncratic reactions

Precautions

Use cautiously in patients with pre-existing liver disease due to risk of hepatotoxicity
Closely monitor patients with cardiac arrhythmias or history of prolonged QT interval
Avoid use in patients with myasthenia gravis or monitor for exacerbation of muscle weakness
Ensure adherence to full course to prevent development of resistant bacterial strains
Monitor electrolyte levels, especially potassium and magnesium, to reduce cardiac risks
Use with caution in elderly patients due to increased risk of side effects such as hearing loss
Avoid concomitant use with drugs known to prolong QT interval unless closely monitored
Adjust dosage appropriately in hepatic impairment; no adjustment usually needed in renal dysfunction
Advise patients about potential gastrointestinal side effects and signs of superinfection
Pregnant and breastfeeding women should use erythromycin only if clearly needed and under medical supervision
Notify healthcare providers about all concomitant medications to prevent drug interactions
Monitor for signs of hypersensitivity reactions during therapy
Avoid crushing or chewing delayed-release formulations to maintain drug efficacy
Counsel patients that erythromycin does not treat viral infections like the common cold or influenza
Be vigilant for signs of antibiotic-associated colitis and discontinue drug if suspected

Warnings

Potential for serious cardiac arrhythmias including torsades de pointes due to QT prolongation
Increased risk of hepatotoxicity, particularly with estolate form; monitor liver function during therapy
Contraindicated concomitant use with cisapride, pimozide, ergotamine, or dihydroergotamine due to risk of severe toxicity
Use caution in patients with known electrolyte abnormalities such as hypokalemia or hypomagnesemia
Risk of Clostridioides difficile-associated diarrhea, which may be fatal; discontinue therapy if suspected
Possible severe allergic reactions including anaphylaxis and Stevens-Johnson syndrome
Risk of superinfections, including fungal infections, with prolonged use
Erythromycin should not be used for viral infections; misuse may promote resistance
Careful dose adjustment and monitoring required in hepatic impairment to avoid accumulation
Not recommended for use in neonates and infants younger than 1 month without specialist supervision
May interfere with results of certain laboratory tests; inform clinicians of erythromycin use
Reports of reversible sensorineural hearing loss at high doses, especially in elderly or renal impairment
Withdrawal slowly to prevent relapse of infection
Avoid combining with other CYP3A4 substrates with narrow therapeutic index without monitoring
Patient should report signs of jaundice, severe abdominal pain, or cardiac symptoms promptly

Contraindication

Known hypersensitivity or allergy to erythromycin or any macrolide antibiotic
Concurrent use with cisapride due to risk of life-threatening cardiac arrhythmias
Concomitant administration with pimozide to avoid serious cardiac adverse events
Use with ergotamine or dihydroergotamine agents is contraindicated because of risk of ergot toxicity
Patients with history of QT interval prolongation or ventricular cardiac arrhythmia
Avoid erythromycin estolate formulation in patients with pre-existing liver disease
Neonates and infants less than one month unless under specialist care
Use contraindicated in patients with hepatic cholestatic jaundice attributed to prior erythromycin therapy
Concomitant use with drugs highly metabolized by CYP3A4 with narrow therapeutic windows unless supervision is possible
Severe liver dysfunction or failure unless benefits outweigh risks

Drug Interactions

Strong inhibition of CYP3A4 leading to increased plasma concentrations of substrates like statins (simvastatin, lovastatin), increasing risk of myopathy or rhabdomyolysis
Increased serum levels and toxicity of calcium channel blockers (e.g., verapamil, diltiazem)
Potential for severe cardiac arrhythmias when combined with other QT-prolonging drugs such as pimozide and cisapride
Enhanced effects and toxicity of oral anticoagulants (warfarin) due to CYP3A4 inhibition, necessitating monitoring of INR
Elevated levels of theophylline and carbamazepine leading to toxicity
Macrolide-induced increased levels of cyclosporine risking nephrotoxicity
Interaction with ergot alkaloids (ergotamine and dihydroergotamine) causing ergotism (severe vasospasm and ischemia)
Antagonism of clindamycin and chloramphenicol, which inhibit protein synthesis by different mechanisms
Reduced efficacy of hormonal contraceptives due to altered gut flora and metabolism (controversial but worth caution)
Additive ototoxic effects when combined with aminoglycosides or loop diuretics
Decreased absorption of cholestyramine when co-administered orally
Possible reduced efficacy of midazolam and triazolam by competitive metabolism alterations
Caution with digoxin as erythromycin may alter its absorption and serum levels
Interference with cyclosporine levels increasing risk for nephrotoxicity
Drugs that induce CYP3A4 (e.g., rifampin, phenytoin) can reduce erythromycin levels, compromising treatment effectiveness

Preparations Of The Drug

Erythromycin base available as tablets, capsules, and suspensions for oral administration
Erythromycin stearate formulated as film-coated tablets and oral suspensions with improved stability
Erythromycin ethylsuccinate in granules for reconstitution and oral suspensions suitable for pediatric patients
Erythromycin estolate (formerly widely used but less now due to hepatotoxicity concerns) formulated as oral tablets and suspensions
Erythromycin lactobionate provided as sterile powder for intravenous injections and infusions
Delayed-release enteric-coated tablets and capsules to improve bioavailability and reduce gastrointestinal irritation
Chewable tablets designed for ease of administration in children
Granules and oral suspensions available in multiple concentrations for flexible dosing in pediatrics
Intravenous formulations intended for serious systemic infections requiring rapid attainment of therapeutic levels
Combination products with other agents (rare and specific indications)
Topical erythromycin preparations (not systemic) for dermatological use, e.g., acne vulgaris – outside scope of systemic erythromycin
Parenteral preparations require reconstitution prior to administration to ensure stability and sterility
Oral liquid formulations contain flavoring agents and suspending vehicles to improve palatability in pediatric patients
Standard packaging includes single-dose vials for injection and multi-dose bottles for oral suspensions
Storage instructions vary by formulation but typically recommend room temperature away from moisture, heat, and light